Probiotic health claims: Reasons to be cheerful?

By Rick Pendrous

- Last updated on GMT

Related tags: Health claims, Immune system, Efsa

Probiotic health claims: Reasons to be cheerful?
Last week's meeting between industry stakeholders and the European Food Safety Authority (EFSA) on gut health claims has left Danisco feeling 'slightly more positive', although many firms were left feeling disappointed by the lack of specific guidance on offer.

To date no probiotic submissions to EFSA’s NDA [dietetic products, nutrition and allergies] panel, which considers health claims, have been successful.

They have either been rejected for insufficient characterisation of the active ingredients and/or lack of evidence ​of efficacy on a healthy population or withdrawn by the companies submitting them.

But Dr Julian Stowell, scientific affairs director at Danisco, told Food Manufacture that he was now slightly more optimistic about the prospects for getting positive approvals on probiotics following a working group meeting on the immune system and digestive health organised by EFSA in Amsterdam last week.

“We are feeling slightly more positive,” ​said Stowell.

Draft guidelines for applicants

Following the meeting, draft guidelines are likely to emerge to help companies supply information in the form that the NDA panel finds acceptable,​ he said.

Stowell was also hopeful that in future biomarkers for disease would be acceptable as a means of proving the efficacy of probiotics in a ‘healthy’ population.

Stowell said Danisco was committed to a strategy predicated on robust science and working to create a more “pragmatic​” regulatory environment for health claims in Europe.

However, he warned that Dansico, which spends around £100m a year on research, could concentrate on other areas of its activities, such as enzymes or in regions of the world such as Japan, if the regulatory environment in Europe proved too difficult.

Growing frustration

While participants at the Amsterdam meeting welcomed the opportunity to quiz EFSA over its approach to gut heath and immunity claims, several suppliers of probiotics at the event felt their concerns about biomarker validation, trial design and disease versus disease risk reduction had not been addressed.

Indeed, Frederic Rene, vice president of research and development at Danone Dairy, told our sister publication Nutraingredients.com​ that he was still none-the-wiser about EFSA’s dossier requirements.

Click here​ to watch a webcast of the meeting.

Click here​ to listen to the Nutringredients podcast with Danone.

Related topics: Legal

Related news

Show more

Follow us

Featured Events

View more

Products

View more

Webinars